Literature DB >> 28179118

Genetic diversity of methicillin resistant Staphylococcus aureus strains isolated from burn patients in Iran: ST239-SCCmec III/t037 emerges as the major clone.

Mehdi Goudarzi1, Mahnaz Bahramian2, Mahboobeh Satarzadeh Tabrizi2, Edet E Udo3, Agnes Marie Sá Figueiredo4, Maryam Fazeli5, Hossein Goudarzi6.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) as a major cause of infection in health care, hospital and community settings is a global health concern. The purpose of this study was to determine the antibiotic susceptibility pattern and distribution of circulating molecular types of MRSA in a burn hospital in Tehran, the capital of Iran. During a 10-month study period, 106 Staphylococcus aureus isolates were assessed. Isolates were subjected to susceptibility testing using the disk diffusion method and Polymerase Chain Reaction (PCR) for detection of mecA, fem and nuc genes. The presence of PVL and tst encoding genes were determined by PCR method. All the MRSA isolates were genotyped by multilocus sequence typing (MLST), spa typing, SCCmec typing and agr typing. The presence of mecA gene was confirmed in all the Staphylococcus aureus isolates. Antimicrobial susceptibility testing revealed a high resistance rate (90.6%) to ampicillin, tetracycline, and erythromycin. The rates of resistance to remaining antibiotics tested varied between 18.9% and 84.9%. The high- level of resistance to mupirocin was confirmed in 19.8% of MRSA strains isolated from burn patients. Multi-drug resistance was observed in 90.6% of isolates. Sixteen of the 106 MRSA isolates (15.1%) harbored PVL-encoding genes. The majority of our MRSA strains carried SCCmec III (71.7%). ST239-SCCmec III/t037 (34%) was the most common genotype followed by ST239-SCCmec III/t030 (24.5%), ST15-SCCmec IV/t084 (15.1%), ST22-SCCmec IV/t790 (13.2%), and ST239-SCCmec III/t631 (13.2%). Mupirocin resistant MRSA isolates belonged to ST15-SCCmec IV/t084 (40%), ST22-SCCmec IV/t790 (23.3%), ST239-SCCmec III/t631 (20%), and ST239-SCCmec III/t030 (16.7%) clones. The results showed that genetically diverse strains of MRSA are circulating in our burn hospitals with relatively high prevalence of ST239-SCCmec III/t037 clone. The findings support the need for regular surveillance of MRSA to determine the distribution of existing MRSA clones and to detect the emergence of new MRSA clones.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Burn patient; MLST; MRSA; SCCmec type; Spa type

Mesh:

Substances:

Year:  2017        PMID: 28179118     DOI: 10.1016/j.micpath.2017.02.004

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  13 in total

1.  Antibiotic resistance profile and molecular characterization of Staphylococcus aureus strains isolated in hospitals in Kabul, Afghanistan.

Authors:  Frédéric Laurent; Céline Dupieux; Haji Mohammad Naimi; Camille André; Michèle Bes; Anne Tristan; Claude-Alexandre Gustave; François Vandenesch; Qand Agha Nazari
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-01-03       Impact factor: 3.267

2.  Molecular Characteristics, Antimicrobial Resistance and Virulence Gene Profiles of Staphylococcus aureus Isolates from Wuhan, Central China.

Authors:  Yu Fu; Mengyuan Xiong; Xuehan Li; Junying Zhou; Xiao Xiao; Fang Fang; Xiaohuan Cheng; Yingbang Le; Yirong Li
Journal:  Infect Drug Resist       Date:  2020-06-30       Impact factor: 4.003

3.  Prevalence, Genetic Diversity, and Temporary Shifts of Inducible Clindamycin Resistance Staphylococcus aureus Clones in Tehran, Iran: A Molecular-Epidemiological Analysis From 2013 to 2018.

Authors:  Mehdi Goudarzi; Nobumichi Kobayashi; Masoud Dadashi; Roman Pantůček; Mohammad Javad Nasiri; Maryam Fazeli; Ramin Pouriran; Hossein Goudarzi; Mirmohammad Miri; Anahita Amirpour; Sima Sadat Seyedjavadi
Journal:  Front Microbiol       Date:  2020-04-30       Impact factor: 5.640

4.  Molecular Characterization of Vancomycin, Mupirocin and Antiseptic Resistant Staphylococcus aureus Strains.

Authors:  Mahtab Hadadi; Hamid Heidari; Hadi Sedigh Ebrahim-Saraie; Mohammad Motamedifar
Journal:  Mediterr J Hematol Infect Dis       Date:  2018-09-01       Impact factor: 2.576

5.  Genetic Variability of Methicillin Resistant Staphylococcus Aureus Strains Isolated from Burns Patients.

Authors:  Mehdi Goudarzi; Nobumichi Kobayashi; Ali Hashemi; Maryam Fazeli; Masoumeh Navidinia
Journal:  Osong Public Health Res Perspect       Date:  2019-06

6.  Molecular Characterization of Methicillin- Resistant Staphylococcus aureus in a Tertiary Care hospital in Kuwait.

Authors:  Wadha Alfouzan; Edet E Udo; Azizah Modhaffer; Asma'a Alosaimi
Journal:  Sci Rep       Date:  2019-12-06       Impact factor: 4.379

7.  Characterization of Staphylococcus aureus isolated from patients with burns in a regional burn center, Southeastern China.

Authors:  Kaisen Chen; Shirong Lin; Peiqun Li; Qiuyue Song; Dong Luo; Tao Liu; Lingbing Zeng; Wei Zhang
Journal:  BMC Infect Dis       Date:  2018-01-25       Impact factor: 3.090

8.  Molecular characterization of vancomycin-resistant Staphylococcus aureus strains isolated from clinical samples: A three year study in Tehran, Iran.

Authors:  Marjan Shekarabi; Bahareh Hajikhani; Alireza Salimi Chirani; Maryam Fazeli; Mehdi Goudarzi
Journal:  PLoS One       Date:  2017-08-30       Impact factor: 3.240

Review 9.  Distribution of the Most Prevalent Spa Types among Clinical Isolates of Methicillin-Resistant and -Susceptible Staphylococcus aureus around the World: A Review.

Authors:  Parisa Asadollahi; Narges Nodeh Farahani; Mehdi Mirzaii; Seyed Sajjad Khoramrooz; Alex van Belkum; Khairollah Asadollahi; Masoud Dadashi; Davood Darban-Sarokhalil
Journal:  Front Microbiol       Date:  2018-02-12       Impact factor: 5.640

10.  Molecular Characterization of Community-Associated Methicillin-Resistant Staphylococcus aureus in Iranian Burn Patients.

Authors:  Samira Tajik; Shahin Najar-Peerayeh; Bita Bakhshi; Reza Golmohammadi
Journal:  Iran J Pathol       Date:  2019-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.